RO7496353 + nivolumab + oxaliplatin + S-1

A combination regimen comprised of four agents for oncology: - **RO7496353** is an investigational monoclonal antibody that selectively inhibits the activation of latent Transforming Growth Factor-beta 1 (TGF-β1), modulating the tumor microenvironment and potentially overcoming tumor-associated immunosuppression. - **Nivolumab** is a checkpoint inhibitor targeting PD-1 (programmed cell death 1), used in immunotherapy to restore anti-tumor T-cell activity. - **Oxaliplatin** is a platinum-based chemotherapy agent that causes DNA crosslinking, inducing tumor cell apoptosis. - **S-1** is an oral fluoropyrimidine chemotherapy consisting of tegafur (a prodrug of 5-FU), gimeracil, and oteracil potassium, which together enhance antitumor efficacy and reduce gastrointestinal toxicity. This combination is currently being investigated for advanced/metastatic solid tumors such as non-small cell lung cancer, gastric cancer, and pancreatic ductal adenocarcinoma[1][2][3][5].

Other names

RO 7496353RO7496353RO-7496353RG 6440RG6440RG-6440